Startups channel feed

Abcuro reels in $155M to test an­ti­body's po­ten­tial in rare mus­cle dis­ease, set­ting biotech's 2026 BLA plans

Last year
Financing

Gilead dish­es out $66M for San Diego biotech's 'ten­ta­cles' in can­cer, in­flam­ma­tion

Last year
Deals

Mary­land biotech Geor­gia­mune nabs $75M to fund three can­cer, au­toim­mune clin­i­cal tri­als 

Last year
Financing

Ike­na inks small cash grab in all-stock deal for Pi­o­nyr to take can­cer drug on Hip­po path­way

Last year
Deals

Born out of Omega push for pan­dem­ic treat­ments, Aeri­um Ther­a­peu­tics en­ters long Covid R&D

Last year
R&D
Coronavirus

De­cen­tral­ized tri­als start­up Cure­base scraps clin­i­cal op­er­a­tions busi­ness unit, nar­rows in on soft­ware plat­form

Last year
People

Play­ground Glob­al, a16z back $26M seed for RNA edit­ing start­up aim­ing to ad­dress mul­ti­ple mu­ta­tions with sin­gle shot

Last year
Financing

Steve Job­s' son to lead Emer­son Col­lec­tive's on­col­o­gy-fo­cused VC firm Yosemite

Last year
Financing

CG On­col­o­gy reels in $105M crossover for po­ten­tial late 2024 blad­der can­cer drug fil­ing

Last year
Financing

In­ter­galac­tic Ther­a­peu­tics, a non-vi­ral gene ther­a­py biotech, lays off all em­ploy­ees

Last year
People
Cell/Gene Tx

Long­wood launch­es start­up Solu with drug can­di­dates from GSK and $31M to start

Last year
Financing

Pe­ter Hecht’s $81M pledge to sal­vage Cy­cle­ri­on as­sets nabs Po­laris sup­port

Last year
Financing

Af­ter EQRx stint, Ja­mi Ru­bin quick­ly re­turns to CFO post at start­up Bound­less Bio

Last year
People

Ri­bon Ther­a­peu­tics rids pre­clin­i­cal work, trims staff to fo­cus on two clin­i­cal PARP in­hibitors

Last year
People

The vet­er­an crew at Medicxi is back with a new $400M fund and an up­beat as­sess­ment of what's com­ing

Last year
Financing
Bioregnum

Jim Mom­tazee's Pa­tient Square leads $150M+ ad­di­tion to Kriya Ther­a­peu­tic­s' 'main­stream' gene ther­a­py am­bi­tions

Last year
Financing
Cell/Gene Tx

Part­nered with Lil­ly, TVM Cap­i­tal and Tillotts fund oral in­flam­ma­to­ry bow­el dis­ease drug with up to $28M

Last year
Financing

Turn­stone Bi­o­log­ics rides biotech's IPO train in Fri­day de­but

Last year
Financing

Scoop: CNS biotech Map­Light Ther­a­peu­tics eyes $175M raise for PhII clin­i­cal tri­als in schiz­o­phre­nia, autism and Parkin­son's

Last year
Financing

Just two years af­ter launch, neu­ro start­up Eliem goes hunt­ing for busi­ness al­ter­na­tives

Last year

Fol­low­ing Dupix­ent’s rise, Sanofi heads down­stream in im­munol­o­gy for $125M small mol­e­cule pact with Re­cludix

Last year
Financing
Deals

Affi­ni-T to close Seat­tle lab as it con­cen­trates in Boston, preps two IND fil­ings in next two months

Last year
People
Cell/Gene Tx

Biotech’s op­ti­mism is re­turn­ing amid signs of a bet­ter sec­ond half and a brighter 2024

Last year
Financing
Deals

ARCH-backed Im­muneID re­struc­tures and search­es for part­ners

Last year
People
First page Previous page 26272829303132 Next page Last page
A service from the Financial Times